Compare HOLO & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOLO | IGC |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4M | 32.0M |
| IPO Year | 2021 | 2005 |
| Metric | HOLO | IGC |
|---|---|---|
| Price | $1.20 | $0.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 199.0K | ★ 637.8K |
| Earning Date | 08-10-2023 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.09 |
| EPS | ★ 1454000.00 | N/A |
| Revenue | ★ $72,512,835.00 | $1,271,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.00 | ★ N/A |
| Revenue Growth | ★ 28.83 | N/A |
| 52 Week Low | $1.33 | $0.24 |
| 52 Week High | $4.98 | $0.45 |
| Indicator | HOLO | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 19.81 | 33.22 |
| Support Level | N/A | $0.24 |
| Resistance Level | $1.69 | $0.30 |
| Average True Range (ATR) | 0.07 | 0.01 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 3.57 | 0.67 |
MicroCloud Hologram Inc provides holographic technology services. Its services include holographic light detection and ranging (LiDAR) solutions, holographic LiDAR point cloud algorithms architecture design, technical holographic imaging solutions, holographic LiDAR sensor chip design, and holographic vehicle intelligent vision technology to service customers that provide holographic driver assistance systems (ADAS). The company also provides holographic digital twin technology services for customers and has built a proprietary holographic digital twin technology resource library. MicroCloud's operating segments are: Holographic technology service, which generates maximum revenue, and Holographic solutions. Its revenues are mainly generated in the People's Republic of China (PRC).
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.